Corporate Profile
True predictive immunotherapy by mimicking the Human Microenvironment (HME)
T
he field of Immuno-oncology, and more broadly Immunotherapy, has been gaining in prominence as the
focus area of much of current cancer dis- covery efforts. Understanding the interac- tion of the immune system with tumour cells has led to development of effective cancer therapies and most recently the Nobel Prize in Medicine. Stimulating a patient’s immune system to
combat diseases such as cancer lies at the heart of the latest immunotherapeutic approaches, and in recent years it has emerged as one of the most promising treat- ment options. Anticancer campaigns have traditionally been confounded by the ability for cancer cells to avoid effective targeting by the immune system. The immune system can appear to be too restrained, too exhausted – unless it is specially outfitted and guided. Measures that can drive the immune system to exert itself more strenu- ously, more aggressively, include monoclon- al antibodies, cancer vaccines, checkpoint inhibitors and adaptive cell therapy – all the tools and techniques of immuno-oncology. At Xcell Biosciences, Inc, a venture-
backed San Francisco-based life science products company, we are developing rev- olutionary clinical research and drug devel- opment products tailored to the immunotherapy market. Xcell Biosciences, Inc is developing revolutionary products and workflows that empower scientists in important fields including cancer research, immunology, stem cell biology and cell therapy development. Xcell’s first product, the AVATAR™ cell control system, offers a powerful new tool allowing for complete control of key physiological conditions found in cellular microenvironments, enabling rapid optimisation of precise con- ditions to achieve long-term cell mainte- nance, expansion and phenotypes of inter- est. We are commercialising the AVATAR™ cell control system for preclinical immunotherapy development and building our next generation of products to disrupt the cell therapy market. Xcell Bio’s technology enables a spectrum
8
of activities across the immunotherapy drug development pipeline, currently estimated to be a $40 billion dollar market. The tech- nology platform enables access to a consis- tent and reliable source of information along three main cell response verticals ben- efiting from primary cell information: 1) on-target effects in primary tumour sam- ples, 2) off-target effects in healthy stem cell-derived populations, and 3) immune cell response as a cell therapy or target of therapy. Researchers use this technology for discovery, translational research and drug screening activities and preclinical research. Xcell Bio is looking to revolutionise the
Ex vivo co-culture of pancreatic ductal adenocarcinoma colonies from fine-needle aspirates. Cancer cells are stained in red and green (EpCAM + CK), non-labelled cells represent the stromal cells derived from the biopsy
The AVATAR™ Cell Control System
control of patient primary cells. Traditional methods are outdated technologies more than 65 years old that lack physiologically- relevant readouts and limit therapeutic potential. As a result, clinical outcomes are less predictive. Xcell Bio’s solutions focus on faster, better and more cost-effective cell therapy drug development and production. Xcell uses its expertise in expanding and modulating phenotype of primary tumour, stem cell and immune cell applications to deliver solutions to the immunotherapy markets. Our technology uses fine control of key environmental conditions in an arrayed format to rapidly seek to a point of optima for cell growth, phenotypic state or func- tional performance. We offer chemically- defined, xeno-free culture medias tailored to major cell categories of interest, expert- backed protocols, and a specialised instru- ment array for fine and flexible environ- mental control across a range of physiolog- ically-relevant conditions. “We are very excited to globally launch
Expression of stemness markers Nanog, Oct4 and Sox2 increase two-fold under hypoxic and pressurised conditions than standard or hypoxia alone (qPCR). Enhanced reprogramming of induced Pluripotent Stem Cells
these transformative and highly impactful technologies for immunotherapy develop- ment, empowering our customers with unprecedented control of physiological human microenvironments,” said Brian Feth, CEO of Xcell Biosciences, “and enabling truly predictive patient responses in precision cancer medicine.” For more information, visit www.xcell-
bio.com, or contact us at
info@xcellbio.com.
Drug Discovery World Fall 2018
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
